Prospective Grant of an Exclusive Patent License: Development and Commercialization of Cell Therapies for Cancer, 6892 [2021-01487]
Download as PDF
<![CDATA[
6892
Federal Register / Vol. 86, No. 14 / Monday, January 25, 2021 / Notices
Licensing Contact: To license this
technology, please contact Carol A.
Salata at 240–627–3727; csalata@
niaid.nih.gov.
The prospective exclusive license
territory may be worldwide, and the
fields of use may be limited to the
following:
Dated: January 14, 2021.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
Dated: January 8, 2021.
Surekha Vathyam,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
Fields of Use Applying to Intellectual
Property Group B
[FR Doc. 2021–01487 Filed 1–22–21; 8:45 am]
[FR Doc. 2021–01490 Filed 1–22–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: Development and
Commercialization of Cell Therapies
for Cancer
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice the inventions embodied in the
Patents and Patent Applications listed
in the Supplementary Information
section of this Notice to Ziopharm
Oncology, Inc. (‘‘Ziopharm’’),
headquartered in Boston, MA.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before February 9, 2021 will be
considered.
SUMMARY:
Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
Exclusive Patent License should be
directed to: Andrew Burke, Ph.D.,
Senior Technology Transfer Manager,
NCI Technology Transfer Center,
Telephone: (240) 276–5484; Email:
andy.burke@nih.gov.
SUPPLEMENTARY INFORMATION:
ADDRESSES:
Intellectual Property
jbell on DSKJLSW7X2PROD with NOTICES
Group B
E–173–2020: T Cell Receptors
Recognizing R273C or Y220C
Mutation in P53
1. U.S. Provisional Patent Application
63/074,747, filed September 4, 2020
(E–173–2020–0–US–01).
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the government of the
United States of America.
VerDate Sep<11>2014
18:31 Jan 22, 2021
Jkt 253001
‘‘Development, manufacture and
commercialization of autologous,
peripheral blood T cell therapy products
engineered by transposon-mediated
gene transfer to express T cell receptors
reactive to mutated P53, as claimed in
the Licensed Patent Rights, for the
treatment of human cancers.
Specifically excluded from this field of
use are CRISPR-engineered peripheral
blood T cell therapy products for the
treatment of human cancers.
Development, manufacture and
commercialization of companion
diagnostics approved or cleared by the
FDA or equivalent foreign regulatory
agency for Licensee-proprietary T cell
therapy products.’’
Intellectual Property Group B is
primarily directed to isolated TCRs
reactive to mutated tumor protein 53
(TP53 or P53), within the context of
several HLAs. P53 is the archetypal
tumor suppressor gene and the most
frequently mutated gene in cancer.
Contemporary estimates suggest that
>50% of all tumors carry mutations in
P53. Because of its prevalence in cancer
and its restricted expression to
precancerous and cancerous cells, this
antigen may be targeted on mutant P53expressing tumors with minimal normal
tissue toxicity.
This Notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published Notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information from these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: Development and
Commercialization of Certain Fusion
Proteins and Their Use for the
Treatment of Humans With Short
Stature
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The Eunice Kennedy Shriver
National Institute of Child Health and
Human Development and the National
Cancer Institute, both institutes of the
National Institutes of Health,
Department of Health and Human
Services, are contemplating the grant of
an Exclusive Patent License to practice
the inventions embodied in the Patents
and Patent Applications listed in the
Supplementary Information section of
this Notice to EpifiZa Inc. of Montreal,
QC (Canada).
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before February 9, 2021 will be
considered.
SUMMARY:
Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
Exclusive Patent License should be
directed to: Richard T. Girards, Jr., Esq.,
MBA, Senior Technology Transfer
Manager, National Institutes of Health,
NCI Technology Transfer Center by
email (richard.girards@nih.gov) or
phone (240–276–6825).
SUPPLEMENTARY INFORMATION:
ADDRESSES:
Intellectual Property
E–003–2014: Agents That Specifically
Bind Matrilin–3 and Their Use/Cartilage
Targeting Agents and Their Use
1. United States Provisional Patent
Application No. 61/927,904, filed 15
January 2014 (HHS Reference No. E–
003–2014–0–US–01);
2. United States Patent No.
10,323,083, issued 18 June 2019 (HHS
Reference No. E–003–2014–0–US–06);
3. United States Patent Application
No. 16/391,101, filed 22 April 2019
E:\FR\FM\25JAN1.SGM
25JAN1
]]>Agencies
[Federal Register Volume 86, Number 14 (Monday, January 25, 2021)]
[Notices]
[Page 6892]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-01487]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: Development and
Commercialization of Cell Therapies for Cancer
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Cancer Institute, an institute of the National
Institutes of Health, Department of Health and Human Services, is
contemplating the grant of an Exclusive Patent License to practice the
inventions embodied in the Patents and Patent Applications listed in
the Supplementary Information section of this Notice to Ziopharm
Oncology, Inc. (``Ziopharm''), headquartered in Boston, MA.
DATES: Only written comments and/or applications for a license which
are received by the National Cancer Institute's Technology Transfer
Center on or before February 9, 2021 will be considered.
ADDRESSES: Requests for copies of the patent applications, inquiries,
and comments relating to the contemplated Exclusive Patent License
should be directed to: Andrew Burke, Ph.D., Senior Technology Transfer
Manager, NCI Technology Transfer Center, Telephone: (240) 276-5484;
Email: [email protected].
SUPPLEMENTARY INFORMATION:
Intellectual Property
Group B
E-173-2020: T Cell Receptors Recognizing R273C or Y220C Mutation in P53
1. U.S. Provisional Patent Application 63/074,747, filed September
4, 2020 (E-173-2020-0-US-01).
The patent rights in these inventions have been assigned and/or
exclusively licensed to the government of the United States of America.
The prospective exclusive license territory may be worldwide, and
the fields of use may be limited to the following:
Fields of Use Applying to Intellectual Property Group B
``Development, manufacture and commercialization of autologous,
peripheral blood T cell therapy products engineered by transposon-
mediated gene transfer to express T cell receptors reactive to mutated
P53, as claimed in the Licensed Patent Rights, for the treatment of
human cancers. Specifically excluded from this field of use are CRISPR-
engineered peripheral blood T cell therapy products for the treatment
of human cancers.
Development, manufacture and commercialization of companion
diagnostics approved or cleared by the FDA or equivalent foreign
regulatory agency for Licensee-proprietary T cell therapy products.''
Intellectual Property Group B is primarily directed to isolated
TCRs reactive to mutated tumor protein 53 (TP53 or P53), within the
context of several HLAs. P53 is the archetypal tumor suppressor gene
and the most frequently mutated gene in cancer. Contemporary estimates
suggest that >50% of all tumors carry mutations in P53. Because of its
prevalence in cancer and its restricted expression to precancerous and
cancerous cells, this antigen may be targeted on mutant P53-expressing
tumors with minimal normal tissue toxicity.
This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and the prospective exclusive license may be granted unless within
fifteen (15) days from the date of this published Notice, the National
Cancer Institute receives written evidence and argument that
establishes that the grant of the license would not be consistent with
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially and may be made
publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information from these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: January 14, 2021.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2021-01487 Filed 1-22-21; 8:45 am]
BILLING CODE 4140-01-P
